Clear Street analyst Kaveri Pohlman initiated coverage of Jade Biosciences (JBIO) with a Buy rating and $25 price target The firm has conviction in JADE101, which it sees as a potential best-in-class anti-APRIL mAb “poised to reshape the IgAN therapeutic landscape.” Jade’s entry into the market “is impeccably timed,” the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JBIO:
- Jade Biosciences price target raised to $17 from $14 at Guggenheim
- Jade Biosciences Advances Autoimmune Therapies
- Jade Biosciences files to sell 16.13M shares of common stock for holders
- Jade Biosciences Reports Q3 2025 Financial Results
- Jade Biosciences: Promising Pipeline and Strategic Expansion Drive Buy Rating